ArticleAAPS PharmSciTech2025
A Novel Felbinac Transdermal Patch with High Permeability: Design, Development and Evaluation.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the work was to design a novel felbinac transdermal patch to improve its transdermal delivery efficiency by adding chemical penetration enhancers. The adhesion properties and in vitro transdermal release performance were first evaluated. The transdermal stability and skin irritation were then evaluated. Moreover, in vivo tissue distribution was also examined. The novel felbinac transdermal patch with high adhesion was prepared by calendar coating method. Different types of chemical enhancers and their amount on in vitro transdermal delivery efficiency were systematically screened. In vitro transdermal release experiments showed that by adding 1% propylene glycol (PG) as penetration enhancers, the cumulative transdermal amount of the transdermal patch within 12 h was 189.03 μg/cm
Indexed as
Identifiers
41044294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.